Loading stock data…
TWST
$69.29-0.75 (-1.07%)
Market OpenUpdated 3:43 PM EDT
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Twist Bioscience Corporation in the Healthcare sector is trading at $69.29. Wall Street consensus targets $64.38 (8 analysts), implying a -7.1% move over the next 12 months. The stock is currently near its 52-week high of $80.50, remaining 67.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$69.29
Potential Downside
0%
Whystock Fair Value$69.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.86%
Volume
Today's trading volume
1.29M
Recent News
Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?
This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.
Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million
This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.
How The Investment Story For Twist Bioscience (TWST) Is Evolving With Recent Developments
Twist Bioscience’s latest analyst update keeps the existing price targets unchanged, with no revisions to the current outlook. Even without fresh commentary from covering analysts, the lack of a price target move itself is a data point worth paying attention to. As you read on, you will see how to track these kinds of shifts in the story so you can stay aligned with the evolving narrative around the stock. Stay updated as the Fair Value for Twist Bioscience shifts by adding it to your...
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Is Twist Bioscience Corporation (TWST) a Strong Buy After Guggenheim Lifts Price Target?
We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Twist Bioscience Corporation (NASDAQ:TWST) is among the best immunology stocks. TheFly reported on May 5 that a Guggenheim analyst increased the price target on TWST from $55 to $60 while maintaining a Buy rating on the stock. The […]